In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
AbCellera Biologics's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.55.
The industry rank for AbCellera Biologics's Net-Net Working Capital or its related term are showing as below:
ABCL's Price-to-Net-Net-Working-Capital is ranked worse than 76.05% of 860
companies
in the Biotechnology industry
Industry Median: 5.545
vs ABCL: 12.35
AbCellera Biologics (NAS:ABCL) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
AbCellera Biologics Net-Net Working Capital Related Terms
AbCellera Biologics Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs AGIO, KOD, IMNM: Net-Net Working Capital Comparison
For the Biotechnology subindustry, AbCellera Biologics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.55 mean?
AbCellera Biologics (ABCL) has a Net-Net Working Capital of $0.55 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on AbCellera Biologics According to the industry distribution chart, AbCellera Biologics ranks #654 out of 860 companies in the Biotechnology industry, placing it in the top 76%.
Is AbCellera Biologics' Net-Net Working Capital too high?
AbCellera Biologics' current Net-Net Working Capital is $0.55. The Biotechnology industry median Net-Net Working Capital is 5.55. AbCellera Biologics' value of $0.55 is 90.1% below this industry median. Based on the distribution chart, AbCellera Biologics ranks #654 out of 860 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Net-Net Working Capital compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #654 out of 860 companies for Net-Net Working Capital. This places AbCellera Biologics in the lower half of its industry. The industry median Net-Net Working Capital is 5.55. AbCellera Biologics' value of $0.55 is 90.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.55, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Net-Net Working Capital of $0.55 is 90.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on AbCellera Biologics For the Biotechnology industry, the median Net-Net Working Capital is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Net-Net Working Capital is $0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.39, compared to a current price of $6.79 — trading 26% above its estimated fair value. The current Net-Net Working Capital is $0.55 and 90.1% below the Biotechnology industry median of 5.55. AbCellera Biologics' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Net-Net Working Capital is $0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $6.79 is trading 26% above its estimated GF Value™ of $5.39.
GuruFocus considers AbCellera Biologics to be Modestly Overvalued.
Key valuation signals for ABCL:
Net-Net Working Capital: $0.55
GF Value™: $5.39 vs. price of $6.79 (26% above fair value)
Industry Position: 90.1% below the Biotechnology median (#654 of 860)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
